Dynamic Pharmacophore Model Optimization: Identification of Novel HIV-1 Integrase Inhibitors
Citations Over TimeTop 10% of 2006 papers
Abstract
We extended the previously described dynamic pharmacophore model studies of HIV-1 integrase (IN) by considering more key residues in the active site, including Mg2+. First, we applied a Monte Carlo sampling method to map the complementary features of the IN binding surface. Two types of dynamic pharmacophore models were generated. One considers Mg2+ as part of the IN and therefore as an excluded volume, and the other treats Mg2+ as a positively charged feature, representing a new type of pharmacophore model aimed to identify compounds potentially preventing Mg2+ binding. Second, we validated the models with 385 known active (IC50 100 microM) inactive IN inhibitors. Third, we used the derived models to screen our small molecule database. Twenty-two structurally novel compounds were tested in an in vitro assay specific for IN, and two of them showed IC50 < or = 10 microM for strand transfer reaction.
Related Papers
- Characterization and structural analysis of HIV-1 integrase conservation.(2009)
- → Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy(2010)73 cited
- → Rational design of 2-pyrrolinones as inhibitors of HIV-1 integrase(2011)68 cited
- → A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series(2008)33 cited
- A theoretical analysis of the relationships between electronic structure and HIV-1 integrase inhibition and antiviral activity of a series of naphthyridinone derivatives(2015)